

- abortion
 and fetal tissue transplantation, 6,8, 10-12,22,24,39,43,72,
 135-136, 151-159
 informed consent issues, 13
 types of, and morally relevant differences among them, 153
- acetylcholine, 35,74-75,97,98
- acetyl-L-carnitine, 99
- adrenal cells, see adrenal cell grafts; chromaffin cells
- adrenal cell grafts
 age of donor and, 66,71,93-94
 animal experiments with, 65-66
 with antiparkinson drugs, 70-71
 cell survival rates, 65-66
 clinical studies of, 68-71
 developmental state of material and success of, 49
 disruption of blood-brain barrier, 53
 effectiveness of, 65, 66,69-71
 for Huntington's disease, 73
 mortality rates, 68, 69-70
 with nerve growth factor, 66, 71
 for Parkinson's disease, 6, 7, 21-22, 23, 45, 52, 62, 65-66,
 68-71
 for progressive supranuclear palsy, 71
 psychological effects of, 52
 registries, 69-70
- adrenocorticotrophic hormone, 106
- Agency for Health Care Policy and Research, 15, 129
- AIDS, 53, 140
- alcohol-dated memory loss, 74
- Alcohol, Drug Abuse, and Mental Health Administration
 funding of neural grafting research, 4,24
 peer review process, 12
- allografts, 23,50,52,78
 FDA regulation of, 126
- aluminum and aluminum binding, 98
- Alzheimer's disease, 7, 19
 animal model of, 74
 cause of, 98
 diagnosis of, 98
 incidence and prevalence of, 3,93,99
 nature of fictional loss in, 20,74,98
 pharmacological treatment of, 98-99
 potential of neural grafts for, 7,74-75,99
 symptoms, 98
- Alzheimer's disease-associated protein, 98
- amantadine, 97
- American Association of Neurological Surgeons, 70
- amygdala, 98
- amyotrophic lateral sclerosis, 7, 20
 cause of, 99
 diagnosis of, 99-100
 incidence and prevalence of, 3, 93, 100
 medical interventions for, 100
 mortality rates, 100
 nature of functional loss in, 99
 potential of neural grafts for, 75, 100
- symptoms of, 99
- amyotrophic lateral sclerosis-Parkinson's disease-dementia, 96
- animal models
 of Alzheimer's disease, 74
 analogous, 61
 of epilepsy, 82
 excitotoxin, 73
 homologous, 61
 MPTP, 63-64,69
 need for, 61, 84
 of neuroendocrine deficits, 83
 6-OHDA, 63,65,66
 of parkinsonism, 23,43,45,63
 of spinal cord injury, 78
 of stroke, 81, 104
- animal research on neural grafting
 with adrenal medullary tissue, 65-66
 for Alzheimer's disease, 74-75
 for amyotrophic lateral sclerosis, 75
 for brain injuries, 81-82
 for epilepsy, 82
 extrapolation to humans, 63
 with fetal CNS tissue, 42-43,63, 65, 72
 focus of, 61
 with genetically engineered cells, 66-67
 for Huntington's disease, 73
 with mature CNS tissue, 49
 for multiple sclerosis, 84
 for Parkinson's disease, 6,63-67
 with peripheral nerve tissue, 43-44
 for spinal cord injuries, 78-79,80
 transition to human studies, 11, 14,22-23,39, 127-128
 types of, 61
- antioxidant, 101
- aspirin, 104
- astrocytes, 29, 30
 effects of grafts from, 47
 function of, 35
 genetic engineering of, 48
- autografts, 23,43,48,50,65,69,78
 FDA regulation of, 126, 127
 of genetically engineered cells, 127
- autonomic nervous system, structure of, 32
- axons
 communication along, 32
 function of, 30,31,76
 growth/regrowth of, 34-36,43,66,78
 structure of, 29
 synaptic pattern of, 34
- basal forebrain, 98
- basal ganglia, 31, 102
- basic research on neural grafting, 3
 Federal funding of, 3,4
 focus of, 61
 needs, 3,4, 19, 21, 39, 53

- benztropine, 97
- beta-amyloid, 98
- Beta-N-methyl amino-L-alanine, 96
- biological rhythms, 42-43
- Biomedical Ethics Advisory Committee, 131
- Biomedical Ethics Board, 131
- blood-brain barrier, 40
 - development within grafts, 50,51
 - disruption by implantation of tissue in CNS, 50,52,53
 - species differences in, 64
- brain
 - developmental sequence in humans, 33-34
 - immunological privilege, 23, 51
 - injury response mechanisms, 66
 - replacement of lost structures in, 41-42
 - structure of, 30-31
 - ventricles, graft placement in, 51, 52
- brain-derived neurotrophic factor, 36
- brain injury, 7, 19
 - animal experiments on, 81
 - causes of, 101-102
 - function of neural grafts in, 7,20,82
 - functional recovery from, 81,82,103-104
 - incidence and prevalence of, 3, 93, 102-103
 - mortality rates, 103
 - nature of, 20
 - neurotrophic activity at wound site, 36
 - from surgical procedure for graft placement, 52
 - see *also* stroke
- brain stem, 31,32,80
- bromocriptine, 97

- calcium channel antagonists, 101
- captopril, 99
- carbidopa, 96
- carotid body cells, 45,65
- catecholamines, 79, 80
- cell lines, 39
 - fetal tissue to start, 10
 - see *also* continuous cell lines
- cell suspensions, 46-47,49,62,72,79,82
 - blood vessel formation in, 51
- cells in culture
 - advantages of, 47-48
 - allografts, FDA regulation of, 127-127
 - see *also* continuous cell lines
- central nervous system
 - fetal, 5
 - immunological privilege, 50, 51
 - lymphatic drainage, 50
 - organization/structure of, 4,5, 29, 30-32
 - regrowth/regeneration in, 4, 34-35
 - see *also* brain; CNS tissue grafts; spinal cord; *and other specific components*
- cerebral cortex, 30, 31,74, 81, 97, 98
- cerebrospinal fluid, 51
- cerebrovascular disease, 102
- CHAMPUS insurance program, 14
- chromaffin cells, 23, 45; see *also* adrenal cell grafts
- ciliary neurotrophic factor, 36
- clinical research on neural grafting
 - with adrenal cells, 67, 68-71
 - cognitive limitations of patients and, 10
 - coordination of, 15, 72-73
 - ethical issues, 3, 10, 161-163
 - Federal regulation of, 8, 13, 14, 113
 - with fetal CNS cells, 67, 71-72; see *also* fetal CNS tissue grafts
 - grievance mechanisms for patients, 121
 - informed consent for, 8, 10, 113, 114-116, 119-121
 - for Parkinson's disease, 14,21,43,61,67-73, 161-162
 - on particularly vulnerable groups, protection of, 116, 119, 121-122
 - privately funded, 11, 12
 - protection of neural graft recipients, 8,10,12,13,23,113-129
 - protocol review and approval, 8, 14
 - selection of subjects, 8, 113
 - State regulation of, 12, 113-116
 - surgical procedures, 67-68
 - withdrawal from experiments, 120
 - see *also* human studies
- CNS tissue grafts
 - adult, 23,49
 - for demyelinating disorders, 84
 - see *also* fetal CNS tissue grafts
- continuous cell lines
 - excessive growth of, 52
 - grafting with, 47-48
 - ownership of, 159-161
- Coordinated Framework for the Regulation of Biotechnology, 122
- corticosteroids, 101
- cryopreservation
 - of adrenal medullary tissue, 68
 - of fetal CNS tissue, 43,45,46
- cycads, and ALS-P-D syndrome, 96

- dementia, prevalence in United States, 99, 102
- demyelinating disorders, 7,20, 102
 - nature of functional loss, 21, 83
 - see *also* multiple sclerosis
- dendrites
 - communication along, 32
 - growth of, 34
 - structure of, 29
- Department of Defense, 8, 14
- Department of Health and Human Services
 - Ethics Advisory Board, 12
 - moratorium on Federal funding of human fetal transplantation research, 6,11,24,39,67,72,128, 149,151,154,171-173
 - protection of neural graft recipients, 8, 12, 13,23, 113
 - see *also* Food and Drug Administration; Public Health Service
- Department of Veterans Affairs, 14-15, 129
 - funding of neural grafting research, 4,8,24
 - spinal cord injury centers, 102
- deprenyl, 64,96, 150
- DiGeorge's syndrome, 151
- dopamine-producing cells, 23,45,62,67
- dorsal roots, regeneration of, 78
- Dunn, E., 21

- encephalitis, 53
- endothelial cells, 51

- epidermal growth factor, 36
- epilepsy, 7, 20, 21
 - animal model of, 82
 - characteristics of, 21, 104
 - drug management of, 105
 - function of neural grafts in, 7, 105
 - incidence and prevalence of, 3, 93, 102, 105
 - types of seizures, 104-105
- ethical issues
 - continuous cell line ownership, 159-161
 - Federal funding and, 9-10, 149-151
 - fetal tissue, 151-159
 - human subjects in research, 3, 10, 161-163
 - Nuremberg Code, 114
 - research abuses, 114
 - sources of materials for transplantation, 3, 6, 10, 22, 23-24, 151-161
 - see *also* medical research ethics
- excitotoxins, 73
- experimental allergic encephalomyelitis, 53
- Federal Food, Drug, and Cosmetic Act, 122, 123, 125
- Federal funding
 - ethical issues in, 149-151
 - moratorium on human fetal tissue transplantation research, 6, 11, 24, 39, 67, 72, 128, 149, 151, 154, 171-173
 - of neural grafting research, 3, 24, 151
 - regulations affecting, 8
- fetal research
 - abortion and, 135-136
 - on cadavers (fetal), 135, 152
 - disposition of remains, 138-139
 - ethical issues in, 152
 - Federal policy development on, 130-131
 - Federal regulations on, 131-132, 138-139
 - grafting, see fetal CNS tissue grafts
 - guidelines on, 8-9
 - interstate transfer of a fetus, 137
 - on live fetuses, 131-132, 135, 153
 - State regulations on, 9, 132-135
- fetal CNS tissue grafts, 39
 - acetylcholine-producing, 75
 - advantages over other tissues, 43, 49
 - for Alzheimer's disease, 74, 75
 - animal experiments with, 42, 43, 63, 65
 - behavioral control with, 42, 43, 83
 - blood vessel formation in, 51
 - for brain injuries, 82
 - brain stem cells, 80
 - from cell suspensions, 46
 - clinical trials, 71-72
 - constraints on use of, 4, 6, 43, 65, 67, 73
 - continuous cell lines from, 136
 - cryopreservation of cells, 43, 45, 46
 - effectiveness of, 4, 22, 42, 53, 65, 66, 72
 - for epilepsy, 82
 - ethical issues in use of, 151-159
 - FDA regulation of, 23, 126, 127
 - Federal oversight of, 9, 138-139
 - for Huntington's disease, 73
 - identification of fetal brain region for materials, 43
 - from induced abortions, 6, 10, 12, 13, 39, 152-157
 - informed consent conditions, 12, 13, 120, 132, 155-156
 - integration into mature CNS, 42
 - manner and timing of procurement of tissues, 12, 23-24
 - norepinephrine-containing, 75
 - number of cells used, 43
 - for Parkinson's disease, 6, 22, 43, 52, 62, 63, 65, 67, 71-72
 - and property rights, 10
 - protection of donors of, 8-9, 129-137
 - and respect for fetal life, 10, 152-152
 - risks to recipients, 43, 136, 152-153
 - sale of materials, 9, 12, 13, 24, 130, 131, 136-137, 140-142, 157-159
 - for spinal cord injuries, 78-80
 - spinal cord tissue, 78-79
 - spinal motor neurons, 75
 - as standard therapy, 157-158
 - survival of grafts, 72
- fibroblast growth factors, 36
- fibroblasts
 - genetic engineering of, 48
 - risk from use in grafts, 48, 53
 - tyrosine hydroxylase production by, 66
- Food and Drug Administration, regulatory authority
 - biological products, 123
 - devices, 123
 - drugs, 122-124
 - interstate commerce and, 124-125
 - limits on, 124-126
 - neural graft materials, 8, 14, 23, 122, 126-127
 - practice of medicine and, 125-126
 - product safety and efficacy, 123-124
- funding, see Federal funding
- gamma-aminobutyric acid, 82, 97, 105
- ganglia, 32
- General Registry of Adrenal-Fetal Transplantation, 70
- genetically engineered cells, 39, 65
 - animal studies with, 66-67
 - autografts of, 127
 - ethical issues related to, 161
 - FDA regulation of, 127
 - grafting methods, 6, 48, 67
 - NGF-producing, 75
- glia-derived nexin, 36
- glial cells
 - differentiation of, 34
 - function of, 29-30, 83
 - inhibition of neuron regrowth, 40
 - primary cultures of, 47
 - replication of, 34
 - Structure of, 29-30
 - types of, 29, 30
- gonadotrophin-releasing hormone, 83
- Health Care Financing Administration, 8, 13, 129
- heart transplants, funding controversies, 150
- hepatitis, 53
- herpes simplex, 53
- hippocampus, 74-75, 82, 98
- HIV, 140
- human amnion membrane matrix, 45
- human studies, see clinical research on neural grafts

- Huntington's disease, 7,20
 - cause of, 73, 97
 - functional loss from, 73,97
 - incidence and prevalence of, 3,93,97-98
 - potential of neural grafts in, 7,73
 - symptoms of, 73, 97
 - treatment of, 97
- hyperexcitable nerve cells, 105
- hypothalamus, 31,82,83
- idebenone, 99
- immune system response
 - to allografts, 52
 - to cell suspensions versus solid tissue grafts, 47
 - developmental state of graft material and, 49
 - to fetal CNS tissue, 43,49
 - to genetically engineered cells, 48
 - multiple sclerosis and, 106
 - Parkinson's disease and, 52
 - prevention of, 50
 - source of tissue and, 5,45, 50-51,53
 - to surgical procedure, 52
- immunological privilege, 23, 50,51
- immunoreactive molecules, 50-51
- immunosuppression, risks to graft recipients, 52
- infections from grafting materials, 53
- informed consent
 - for donation of continuous cell lines, 159-161
 - ethical issues, 162-163
 - for fetal tissue donation, 12, 13, 132, 155-156
 - information to be provided for, 119-120
 - from particularly vulnerable populations, 121-122
 - from patients in clinical studies, 8, 10, 113, 119-121
 - penalties for violation of, 120-121
 - State regulations on, 114-116, 119-121
 - withdrawal from experiments, 120
- injury, see brain injury; spinal cord injury
- Institutional Review Boards, 8, 12, 14, 15,23, 161
 - composition of, 118
 - criteria for authorization of human research, 117
 - ethical guidelines, 117-118
 - Federal requirements for review by, 129
 - procedure for obtaining approval of, 118
 - purpose of, 113, 116-119
 - State requirements for review by, 122
- insulin and insulin-like growth factors, 36
- Interagency Head Injury Task Force, 102-103
- interstate commerce, and regulation of neural grafting, 124-125
- isografts, 50
- Joint Commission on Accreditation of Healthcare Organizations, 8, 129
- L-dopa
 - production by genetically engineered cells, 48
 - treatment of Parkinson's disease with, 95-97, 150
- laminin, 36
- legal/regulatory issues
 - constitutionality of restrictions on research, 9, 137-138
 - disposition of cadavers/fetal remains, 9, 13, 138-139
 - Federal oversight, 9, 14, 137-142
 - fetal research, 131-132, 138-139
 - grievance mechanisms for patients, 121
 - indirect regulation, 8, 14, 129
 - informed consent, 8, 12, 13, 119-121
 - neural graft materials, see Food and Drug Administration
 - ownership of continuous cell lines, 159-161
 - payment of donors, 8,9,140-142
 - protection of donors of fetal tissue, 8-9, 129-137
 - protection of human subjects in research, 8, 13,22, 113-129;
 - see also *clinical* research on neural grafting; informed consent; State laws
 - see also *specific statutes*
- limbic system, 31
- locus ceruleus, 82,98
- Lou Gehrig's disease, see amyotrophic lateral sclerosis
- Medical Device Amendments of 1976, 124
- medical malpractice, 8
- medical research ethics, genesis of, 114
- Medical Treatment Effectiveness Program, 15
- Medicare/Medicaid coverage, 14, 129
- l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 64,95
- methylprednisolone, 101, 106
- methylpyridine, 64
- microglia, 29, 30
- milacemide, 99
- monoamine oxidase B, 64
- moratorium on Federal funding of human fetal transplantation research, 6,11,24,39,67,72,128, 149,151,154,171-173
- motor neurons, neural grafting with, 100
- motor neuron disease
 - potential of neural grafts in, 7,75
 - see also amyotrophic lateral sclerosis
- MPTP model of parkinsonism, 63-64,95
- multiple sclerosis, 7, 21
 - causes of, 105-106
 - death rates, 106
 - diagnosis of, 106
 - drug therapy, 106
 - and immune system function, 106
 - incidence and prevalence, . of 3, 93, 106-107
 - potential of neural grafts in, 84, 106
 - symptoms of, 105
- myelin
 - formation of, 34,43,47,83
 - function of, 29,43
 - loss of, 21, 105; see also multiple sclerosis
- naloxone, 101
- National Academy of Sciences, 12
- National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 130, 151-152
- National Conference of Commissioners on Uniform State Laws, 13, 140
- National Institute of Neurological Disorders and Stroke, 70
- National Institutes of Health
 - budget, 113
 - funding of neural grafting research, 4,24
 - guidelines for neural grafting research protocols, 15
 - guidelines for research on vulnerable subjects, 121
 - Human Fetal Tissue Transplantation Research Panel, 12,154
 - peer review process, 12
- National Organ Transplant Act

- components covered under, 13-14
- fetal tissue regulation under, 9, 12-13, 141, 157
- National Research Act, 130
- National Science Foundation, funding of neural grafting research, 4, 24
- nerve fibers, 45,62
- nerve growth factor
 - with adrenal cell grafts, 66,71
 - and Alzheimer's disease, 98
 - production by genetically engineered cells, 48
 - protection of acetylcholine neurons, 75,98-99
 - role of, 36
 - stimulation by grafts, 41
- nerve roots, 31-32
- nervous system
 - cellular components of, 29-30; see *also* glial cells; neurons
 - chemical-electrical communication in, 32-34
 - fetal (human), 43
 - organization/structure of, 4,5, 29-32
 - see *also* brain; central nervous system; peripheral nervous system; spinal cord; *and other specific components*
- neural grafting
 - age of host and, 51-52,53,78-79
 - alternatives to, 150-151
 - and blood vessel formation, 51, 53
 - definition of, 3,4,39
 - effectiveness on neurological disorders, 19,61,63-64,93
 - Federal interests in, 22-24
 - historical perspective, 21-23,42
 - with immature versus mature tissue, 5, 21,49,52,53,66
 - number of cells used in, 52
 - number of recipients, 19
 - Nuremberg Code applied to, 114
 - psychological effects of, 52,69
 - replacement of chemicals with, 19,20, 39,40,42
 - replacements of lost structures with, 19,20,39,41-42
 - risks to recipients, 5, 42, 52-53, 81, 152-153, 161-162; see *also immune* system response
 - site for transplantation, 44, 62, 63,72
 - stimulation of cell growth and survival with, 19,20,40-41,63, 80
 - success factors in, 5,49-51
 - therapeutic strategies, 4, 19,39-42
- neural grafting materials, 4-5,6, 53
 - ethical and legal questions, 42, 151-161; see *also ethical* issues; legal/regulatory issues
 - excessive growth of, 52
 - immunological problems of, 42
 - infections from, 53
 - man-made, coated with growth-promoting chemical, 45
 - regulation of, 8, 23, 122
 - sources of, 23,39,42
 - see *also* adrenal cell grafts; fetal CNS tissue grafts; genetically modified cells
- neuritic plaques, 98
- neuroblastoma cells, 47
- neurodegenerative disorders, 20
 - characteristics of, 20
 - potential function of neural grafts in, 7
 - see *also specific diseases*
- neuroendocrine deficits, 7, 82-83
- neurofibrillary tangles, 98
- neurological disorders
 - animal models of, 43
 - costs of, 7, 93, 150
 - disease, 20-21; see *also* neurodegenerative disorders, *and specific disorders*
 - epidemiology of, 94-100
 - incidence and prevalence of, 3, 19,93
 - injury, 20; see *also* brain injury; spinal cord injury
 - nature of, 20-21
 - potential of neural grafting for, 150
 - treatment approaches, 3,7, 19,21
 - in veterans, 102
 - see *also specific disorders*
- neuromuscular diseases, 102
- neurons
 - death of, 34,41,94,97,98
 - differentiation of, 34
 - injured, 40-41
 - number of, 34
 - peripheral autonomic, 5
 - primary cultures of, 47
 - regeneration of, 29, 34-35,40,45
 - structure of, 29
 - survival of grafting procedures, 43,47
 - see *also axons*; dendrites
- neurotransmitters, 7,44,45,73
 - function of, 32-33
 - implants in CNS, 40
 - kinds of, 33-34
 - see *also specific neurotransmitters*
- neurotrophic factors, 34, 36,66,79, 82
- neurotrophin-3, 36
- neurotropic factors, 34, 36,79
- nimodipine, 99
- noradrenaline, 82,98
- nucleus/nuclei
 - defined, 30
 - purpose of, 31
- Nuremberg Code, 114
- 6-OHDA, 63,65,66
- oligodendrocytes
 - function of, 29,30,35,47,83
 - primary cultures of, 47
- organic brain syndrome, 102
- paraneurons, 45
- Parkinson, James, 94
- Parkinson's disease and parkinsonism, 7, 19
 - adrenal cell grafts for, 21-22,45,62,65-66,67, 68-71, 128
 - animal research *on*, 23,43,45,63-67
 - causes of, 95
 - clinical trials of neural grafting, 14, 21, 43, 61, 67-72, 128, 161-162
 - drugs used for treatment of, 97, 150
 - epidemiology of, 94-97
 - fetal CNS grafts for, 6,22,43,52,62,63,65, 67,71-72,136
 - genetically engineered cell grafts for, 66-67
 - incidence and prevalence of, 3,93,95,96-97
 - mortality rates, 68, 69-70
 - MPTP model, 63-64,66,95
 - nature of functional loss in, 20, 62, 94

- neural grafting applications, 3, 5, 6,96
- number of recipients of neural grafts, 6, 67
- on-off phenomenon, 68
- registries, 69-70
- site for transplantation, 62, 63
- success of neural grafting in, 5,39,63,71,72,84,93, 150-151
- surgical procedures for grafts, 67-68
- symptoms, 62,64,94,95
- treatment of, 95-96
- PC12, 47
- peripheral autonomic tissue
 - animal experiments with, 44-45
 - developmental state of, and success of graft, 49
- peripheral nerve cells
 - function of, 44
 - grafts with, 23,39,43-44,45,78,84
 - regrowth of, 44
- peripheral nervous system
 - organization/structure of, 4, 29, 32
 - regrowth/regeneration in, 4, 34-35
 - tissues used for grafting, 5
- physostigmine, 99
- pituitary gland, 82
- policy issues and options
 - Federal funding of fetal tissue transplantation research, 11-12
 - Federal Government role in development of neural grafting procedures, 14-15
 - laws and regulations applicable to fetal tissue transplantation, 12-14
- practice of medicine, and regulation of neural grafting, 125-126
- progressive supranuclear palsy, 71
- Protection of Human Subjects Act, 155
- Public Health Service Act, 8, 122, 123, 125-127
- regulatory issues, see legal/regulatory issues
- research, see animal research; basic research; clinical research
- retrograde cell death, 76, 78
- S100 protein, 36
- scar formation, 41
 - astrocytes and, 35, 47
 - reduction of, 47,78
- Schwann cells, 29,30
 - axonal regrowth into, 35
 - function of, 34,43,47,83
 - from peripheral nerves, 84
 - in primary cultures, 47
- seizures, 21, 53, 82, 104; see *also* epilepsy
- sexual potency/sexual behavior, restoration of, 83
- spinal cord
 - immunological privilege, 51
 - regenerative capacity, 80
 - replacement of lost structures in, 41-42, 76
 - structure of, 31-32, 76
- spinal cord injury, 7, 19
 - age of host and effectiveness of grafts, 78-79
 - animal models of, 78
 - causes of, 75, 100
 - demyelination in, 84
 - effectiveness of grafts on, 80-81
 - fetal brain tissue grafts, 79
 - fetal spinal cord tissue grafts, 78-79
 - fictional losses from, 102
 - functional recovery from, 79-80,80-81, 101
 - incidence and prevalence of, 3,93, 101, 102
 - and neurotrophic and neurotropic factors, 79
 - peripheral nerve grafts for, 78
 - potential function of neural grafts in, 7,76-78, 101
 - rehabilitative therapy, 81
 - repair of nerve fibers, 76
 - research needs on, 80
 - risks to graft recipients, 81
 - sources of graft materials, 79
 - survival rates, 101
- State laws
 - on clinical research, 12, 113-116, 121-122
 - on compensation for fetal tissue, 140-142
 - on disposal of fetal remains, 138-139
 - on fetal research, 9, 132-135
 - on informed consent, 114-116, 119-121
 - licensing, 8
 - on protection of fetus, 132-135
 - on protection of particularly vulnerable populations, 121-122
 - on protection of pregnant women, 140; see *also* informed consent
- striatum, 62,67-68,72, 73,97
- stroke, 7, 19
 - animal model of, 81
 - causes of, 102
 - functional losses from, 103
 - incidence and prevalence of, 3, 93, 104
 - intracranial hemorrhage, 103
 - ischemia, 103
 - potential of neural grafting for, 81-82, 104
- substantia nigra, 62, 63, 70, 94
- surgical procedures
 - adrenalectomy, 68,69-70
 - clinical trials of, 128
 - complications of, 68, 69-70
 - effect of graft placement during, 52
 - effect on success of graft, 66
 - for epilepsy, 105
 - open surgery, 67, 69
 - for Parkinson's disease grafts, 67-68,72
 - regulation of, 8, 127-129
 - stereotactic, 67, 72
- suronacrine maleate, 99
- sympathetic ganglia, 65
- synapses
 - between graft and host, 40,62-63,73,82
 - structure of, 32-33
- synaptic contacts, 34, 36, 76, 80
- synaptic space, defined, 32
- synaptic sprouting, 34-35
- tetrahydroaminoacridine, 99
- thalamus, 31
- Thompson, W. G., 21
- thyrotropin-releasing hormone, 101
- transplants, tissue and organ, number of recipients, 19
- trihexyphenidyl, 97
- tumor formation, from continuous cell lines, 48,52
- Tuskegee syphilis study, 114
- tyrosine hydroxylase, 66

Uniform Anatomical Gift Act
 amendment of, 13
 applicability to fetal tissue implants, 9,13, 135,136,138-141,
 154
uniform donor card, 139
United Parkinson Foundation, 70

vasopressin, 83
velnacrine maleate, 99

Willowbrook hepatitis study, 114

xenograft, 50, 53